Status:
UNKNOWN
Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
Lead Sponsor:
University Hospital, Saarland
Conditions:
Follicular Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation...
Eligibility Criteria
Inclusion
- standard radioimmunotherapy with 90-yttrium-labeled anti-CD20-antibodies in treatment of relapsed and/or refractory follicular NHL or partial remission after induction chemotherapy
- finding of at least one image-guided measurable lymphoma lesion
- existence of FDG-PET- and CT-image data of at most 8 weeks before treatment
- signed patient´s agreement for RIT registry and MERIT-NHL
Exclusion
- other therapy modalities than standard radioimmunotherapy (e.g. consolidation)
- solely CNS-lymphoma or primary effusion lymphoma
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01151358
Start Date
May 1 2008
End Date
December 1 2011
Last Update
June 28 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Nuclear Medicine, Saarland University Hospital
Homburg (Saar), Saarland, Germany, 66421
2
Klinikum Karlsruhe, Dept. of Nuclear Medicine
Karlsruhe, Germany
3
University Clinic Kiel-Luebeck
Lübeck, Germany, 23538
4
Technical University, Dept. of Nuclear Medicine
Munich, Germany